Prelude Therapeutics Incorporated

Latest Results (06.11.2025):

Prelude Therapeutics Incorporated reported its financial results for the second quarter of 2025, highlighting progress in its clinical programs alongside a disciplined expense management approach. The company achieved a cash position of $77.3 million as of June 30, 2025, with a net loss of $31.2 million for the quarter, reflecting lower research and development and general and administrative expenses compared to the same period in 2024. Amid these financial updates, Prelude is strategically shifting its SMARCA2 program focus to its oral candidate PRT7732, while also advancing its KAT6A degrader program towards an IND filing in the first half of 2026.

Financial Position and Cash Runway

As of June 30, 2025, Prelude Therapeutics held $77.3 million in cash, cash equivalents, restricted cash, and marketable securities. This strong cash position is expected to fund operating activities into the second quarter of 2026, underscoring effective capital management during the ongoing clinical trials and development initiatives.

Expense Management and Net Loss

The company reported a decrease in both R&D expenses ($25.8 million vs. $29.5 million in Q2 2024) and G&A expenses ($6.4 million vs. $7.7 million in Q2 2024), partly due to reduced stock-based compensation charges. Net loss improved to $31.2 million, or $0.41 per share, compared to $34.7 million, or $0.46 per share, in the prior year quarter.

Clinical Pipeline and Strategic Focus

Prelude is advancing its oral SMARCA2 degrader PRT7732, currently enrolling patients in the seventh dose cohort, and has paused further development of its intravenous candidate PRT3789. Additionally, the company is progressing its KAT6A degrader program—targeting IND filing in early 2026—and is nurturing developments in precision ADCs and other oncology targets to address unmet medical needs in the precision oncology space.